OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free BPMUF Stock Alerts $40.75 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$40.75▼$40.7550-Day Range$38.60▼$41.0052-Week Range$38.60▼$40.75VolumeN/AAverage VolumeN/AMarket Capitalization$482.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Basilea Pharmaceutica alerts: Email Address Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Read More BPMUF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMUF Stock News HeadlinesMarch 11, 2024 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaFebruary 21, 2024 | investing.comBasilea Pharmaceutica AG (BSLN)March 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 13, 2024 | finance.yahoo.comBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioJanuary 19, 2024 | finance.yahoo.comCresemba® sales in Latin America trigger first sales milestone payment to BasileaJanuary 15, 2024 | markets.businessinsider.comBasilea To Buy Preclinical Antibiotics Program From SpexisJanuary 15, 2024 | finance.yahoo.comBasilea announces acquisition of preclinical antibiotics program from SpexisJanuary 5, 2024 | finance.yahoo.comBasilea provides portfolio status updateMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.December 20, 2023 | markets.businessinsider.comBasilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured LoanDecember 20, 2023 | finance.yahoo.comBasilea announces accelerated loan repaymentDecember 11, 2023 | finance.yahoo.comBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisDecember 4, 2023 | finance.yahoo.comBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsNovember 20, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearNovember 13, 2023 | msn.comPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalNovember 13, 2023 | finance.yahoo.comBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalOctober 31, 2023 | finance.yahoo.comBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentOctober 19, 2023 | finance.yahoo.comBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infectionsOctober 17, 2023 | finance.yahoo.comBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023October 2, 2023 | finance.yahoo.comBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiproleSeptember 28, 2023 | finance.yahoo.comBasilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremiaAugust 15, 2023 | finance.yahoo.comBasilea reports strong revenue and profit growth in first half-year 2023August 4, 2023 | markets.businessinsider.comBasilea Pharma Submits NDA For Antibiotic CeftobiproleAugust 4, 2023 | finance.yahoo.comBasilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiproleJune 8, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to BasileaApril 18, 2023 | finance.yahoo.comBasilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiproleFebruary 14, 2023 | markets.businessinsider.comBasilea Pharmaceutica Posts FY ProfitSee More Headlines Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:BPMUF CUSIPN/A CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees147Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio7.55 Current Ratio3.20 Quick Ratio2.38 Sales & Book Value Annual Sales$175.50 million Price / Sales2.75 Cash Flow$1.13 per share Price / Cash Flow36.06 Book Value($1.83) per share Price / Book-22.27Miscellaneous Outstanding Shares11,850,000Free FloatN/AMarket Cap$482.89 million OptionableNot Optionable Beta0.65 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. David Veitch (Age 59)Chief Executive Officer Comp: $1.26MMr. Adesh Kaul (Age 50)Chief Financial Officer Dr. Gerrit Hauck Ph.D. (Age 60)Chief Technology Officer Dr. Laurenz Kellenberger Ph.D. (Age 57)Chief Scientific Officer Dr. Marc Engelhardt M.D. (Age 60)Chief Medical Officer Dr. Peer Nils SchroderHead of Corporate Communications & Investor RelationsMr. Damian Heller (Age 58)General Counsel & Corporate Secretary Mr. Andreas KuminHead of Corporate DevelopmentMs. Ursula Eberhardt (Age 62)Head of Global Human Resources Mr. Mark Jones (Age 56)Head of Project Management & Preclinical Development More ExecutivesKey CompetitorsAlto NeuroscienceNYSE:ANROLexicon PharmaceuticalsNASDAQ:LXRXMarinus PharmaceuticalsNASDAQ:MRNSNkartaNASDAQ:NKTXRevance TherapeuticsNASDAQ:RVNCView All Competitors BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed in 2024? Basilea Pharmaceutica's stock was trading at $41.00 on January 1st, 2024. Since then, BPMUF shares have decreased by 0.6% and is now trading at $40.75. View the best growth stocks for 2024 here. Are investors shorting Basilea Pharmaceutica? Basilea Pharmaceutica saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 215,600 shares, a decrease of 14.3% from the February 14th total of 251,600 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. View Basilea Pharmaceutica's Short Interest. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Basilea Pharmaceutica have any subsidiaries? The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.Read More This page (OTCMKTS:BPMUF) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.